AGTC Genomics

22/04/2026

𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗨𝗻𝘃𝗲𝗶𝗹𝘀 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝗗𝗮𝘁𝗮 𝗮𝘁 𝗔𝗔𝗖𝗥 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟲 𝗗𝗲𝗺𝗼𝗻𝘀𝘁𝗿𝗮𝘁𝗶𝗻𝗴 𝗦𝘁𝗿𝗼𝗻𝗴 𝗣𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗼𝗳 𝗠𝘂𝗹𝘁𝗶-𝗖𝗮𝗻𝗰𝗲𝗿 𝗘𝗮𝗿𝗹𝘆 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 (𝗠𝗖𝗘𝗗)

AGTC Genomics announced the latest breakthrough clinical validation data at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22, 2026 in San Diego, USA, one of the world’s most prestigious platforms for cutting-edge cancer research.

The study highlights the strong clinical performance of AGTC Genomics’ CancerScreenDx Multi-Cancer Early Detection (MCED) test using circulating cell-free DNA (cfDNA), reinforcing its potential as a scalable and non-invasive cancer screening solution.

𝗥𝗼𝗯𝘂𝘀𝘁 𝗔𝗰𝗰𝘂𝗿𝗮𝗰𝘆 𝗳𝗼𝗿 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴

The multi-centre clinical validation study, comprising 2,342 cancer patients and 1,646 non-cancer individuals, demonstrated:

• Overall Sensitivity: 83.1%
• Specificity: 95.4%
• Low False Positive Rate: 4.6%

These results underscore the test’s ability to accurately distinguish cancer from non-cancer individuals—meeting key performance thresholds required for population-level screening.

𝗦𝘁𝗿𝗼𝗻𝗴 𝗘𝗮𝗿𝗹𝘆 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗖𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝘆

Early detection remains the most critical factor in improving cancer survival. The study showed:

• Stage I–II Sensitivity: 75.0% – 91.3%
• Stage III–IV Sensitivity: 95.5% – 100%

Importantly, the MCED assay demonstrated strong detection performance across multiple high-burden cancers relevant to Asia, including liver, gastric, pancreatic, bile duct, and nasopharyngeal cancers—areas where early diagnosis is often challenging.

𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗠𝘂𝗹𝘁𝗶-𝗠𝗼𝗱𝗮𝗹 𝗚𝗲𝗻𝗼𝗺𝗶𝗰 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵

AGTC Genomics’ MCED platform integrates:

• Targeted cfDNA mutation profiling
• Genomic signature analysis
• AI-driven machine learning algorithms

This integrated approach enables detection of cancer signals from a simple blood draw, offering a non-invasive, radiation-free alternative to conventional screening methods.

𝗚𝗹𝗼𝗯𝗮𝗹 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝗼𝗻 𝗮 𝗣𝗿𝗲𝘀𝘁𝗶𝗴𝗶𝗼𝘂𝘀 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺

The presentation at AACR 2026—recognized globally as a premier forum for breakthrough oncology research—marks a significant milestone for AGTC Genomics in advancing precision oncology innovation from Asia to the world.

𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗣𝗮𝗿𝗮𝗱𝗶𝗴𝗺

The findings support MCED as:

• A single-test solution for detecting multiple cancers
• A complementary tool to existing screening programs
• A population-scale strategy to shift cancer detection earlier

By enabling earlier diagnosis, MCED has the potential to significantly reduce cancer mortality and healthcare burden across the region.

22/04/2026

𝗕𝗥𝗘𝗔𝗞𝗧𝗛𝗥𝗢𝗨𝗚𝗛: 𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗨𝗻𝘃𝗲𝗶𝗹𝘀 𝗟𝗮𝗻𝗱𝗺𝗮𝗿𝗸 𝗠𝗖𝗘𝗗 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝗮𝘁 𝗔𝗔𝗖𝗥 𝟮𝟬𝟮𝟲

At one of the world’s most influential cancer research platforms, the AACR Annual Meeting 2026, AGTC Genomics presented clinical validation data that signals something important:

Multi-Cancer Early Detection (MCED) is moving from promise to practicality.

This is not just about numbers.
This is about what those numbers mean.

When a test can detect cancer before symptoms appear, with strong accuracy and low false positives, it changes the entire equation:

• From late-stage treatment → early intervention
• From reactive care → proactive health
• From single-cancer screening → multi-cancer insight in one test

What stood out is the consistency of performance across stages, including early-stage cancers — the exact window where lives can be saved.

Even more important, this was demonstrated across cancers that matter most in our region:

liver, gastric, pancreatic, bile duct, nasopharyngeal

These are cancers where:

• Screening is limited
• Diagnosis often comes late
• Outcomes are heavily stage-dependent

This is where MCED can have real-world impact.

Why this matters

For clinicians:
→ A new tool to identify risk earlier, when treatment is still curative

For healthcare systems:
→ A scalable strategy to reduce late-stage burden and cost

For patients:
→ A simple blood test that could mean the difference between early detection and missed opportunity

𝗧𝗵𝗲 𝗯𝗶𝗴𝗴𝗲𝗿 𝗽𝗶𝗰𝘁𝘂𝗿𝗲

We are entering a phase where:

• Genomics + AI are no longer experimental
• Population-scale screening is becoming feasible
• Precision medicine is shifting upstream — into prevention

MCED is not here to replace existing screening.
It is here to connect the gaps where screening does not exist.

At AGTC Genomics, the focus remains clear:

Right test. Right time. Right impact.

The future of cancer care will not be built on better treatment alone —
It will be built on detecting cancer before it becomes a problem.

San Diego, USA – April 2026 — AGTC Genomics today announced the latest breakthrough clinical validation data at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22, 2026 in San Diego, USA, one of the world’s most prestigious platforms for cutting-edge ca...

20/04/2026

𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗮𝘁 𝗥𝗖𝗣𝗛 𝟮𝟬𝟮𝟲: 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗛𝗲𝗮𝗹𝘁𝗵 𝗶𝗻 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮

AGTC Genomics was pleased to participate in the 1st Regional Conference on Precision Health (RCPH) 2026, held at Royale Chulan Kuala Lumpur and organized by UKM Medical Molecular Biology Institute (UMBI).

A key highlight was the launch of the 1st Malaysian Pangenome, marking an important step toward building population-relevant genomic data to support precision health in Malaysia.

At the conference, AGTC Genomics showcased how multi-cancer early detection (MCED) can be developed and deployed in real-world settings—enabling early identification of cancer signals in asymptomatic individuals. In several cases, this has helped preserve the critical window for curable cancers, potentially saving lives that might otherwise have been missed.

Localizing and building precision medicine capacity remains crucial for precision public health, with a strong emphasis on making these technologies more accessible and affordable for broader population impact.

Advancing precision medicine is not just about innovation—it’s about impact, access, and equity.

AGTC Genomics Showcases Leadership in Precision Medicine at 1st Regional Conference on Precision Health (RCPH) 2026

19/04/2026

𝗣𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿 𝗜𝘀 𝗦𝗶𝗹𝗲𝗻𝘁. 𝗬𝗼𝘂𝗿 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗦𝗵𝗼𝘂𝗹𝗱𝗻’𝘁 𝗕𝗲.

Pancreatic cancer is one of the most aggressive cancers—often detected only when symptoms appear, and by then, options are limited.

Waiting is not a strategy.

With AGTC Genomics CancerScreenDx (MCED), you can now offer:
✔ Early cancer signal detection from a simple blood test
✔ Screening before symptoms like pain, weight loss, or jaundice
✔ Multi-cancer detection in a single workflow
✔ A powerful addition for high-risk patient monitoring

This is not just screening.
This is your opportunity to detect one of the deadliest cancers earlier.

🚀 Why Clinics Are Moving Toward MCED
• Identify high-risk patients earlier (family history, diabetes, chronic pancreatitis)
• Move beyond symptom-driven diagnosis
• Strengthen your preventive and executive health programs
• Offer advanced genomics screening patients are actively seeking
• Unlock new high-value diagnostic revenue streams

🚨 Opportunity for Clinics & Doctors

• Expand your preventive health portfolio
• Differentiate your practice with advanced genomics
• Increase patient retention with proactive screening programs
• Generate new revenue streams with high-value diagnostics

Don’t wait for late-stage cases.
Start detecting earlier. Start saving more lives.

📩 Partner with AGTC Genomics today
📍 Deploy CancerScreenDx in your clinic
🔬 Backed by advanced NGS & precision medicine expertise

19/04/2026

𝗟𝗶𝘃𝗲𝗿 𝗖𝗮𝗻𝗰𝗲𝗿 𝗜𝘀 𝗗𝗲𝘁𝗲𝗰𝘁𝗲𝗱 𝗧𝗼𝗼 𝗟𝗮𝘁𝗲. 𝗬𝗼𝘂𝗿 𝗖𝗹𝗶𝗻𝗶𝗰 𝗗𝗼𝗲𝘀𝗻’𝘁 𝗛𝗮𝘃𝗲 𝘁𝗼 𝗔𝗰𝗰𝗲𝗽𝘁 𝗧𝗵𝗮𝘁.

Most liver cancer patients are diagnosed at advanced stages—despite being in regular follow-up for HBV, HCV, or fatty liver disease.

That’s not a patient problem.
That’s a screening gap.

With AGTC Genomics CancerScreenDx (MCED), you can now:
✔ Detect liver cancer signals earlier—before imaging picks it up
✔ Go beyond AFP and ultrasound limitations
✔ Screen high-risk patients proactively, not reactively
✔ Offer multi-cancer detection in a single blood test

This is not incremental improvement.
This is a new standard for liver cancer surveillance.

🚀 Why Forward-Looking Clinics Are Switching Now
• Capture high-risk chronic liver patients earlier (HBV, HCV, NAFLD/NASH)
• Reduce missed early-stage cases from conventional surveillance
• Upgrade your hepatology and preventive care programs
• Differentiate your clinic with advanced genomics capability
• Generate consistent, high-value screening revenue from follow-up patients

🚨 Opportunity for Clinics & Doctors

• Expand your preventive health portfolio
• Differentiate your practice with advanced genomics
• Increase patient retention with proactive screening programs
• Generate new revenue streams with high-value diagnostics

Don’t wait for late-stage cases.
Start detecting earlier. Start saving more lives.

📩 Partner with AGTC Genomics today
📍 Deploy CancerScreenDx in your clinic
🔬 Backed by advanced NGS & precision medicine expertise

18/04/2026

🎨 𝗗𝗲𝘀𝗶𝗴𝗻 𝗦𝗼𝗺𝗲𝘁𝗵𝗶𝗻𝗴 𝗧𝗵𝗮𝘁 𝗔𝗰𝘁𝘂𝗮𝗹𝗹𝘆 𝗠𝗮𝘁𝘁𝗲𝗿𝘀
🚀 𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗶𝘀 𝗛𝗶𝗿𝗶𝗻𝗴: 𝗚𝗿𝗮𝗽𝗵𝗶𝗰 𝗗𝗲𝘀𝗶𝗴𝗻𝗲𝗿 𝗜𝗻𝘁𝗲𝗿𝗻

Most internships give you tasks.
This one gives you ownership, impact, and a portfolio that stands out.

At AGTC Genomics, you won’t just design pretty visuals —
you’ll turn complex genomics and healthcare innovations into powerful visual stories that reach clinicians, researchers, and the public.

💡 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂’𝗹𝗹 𝗚𝗲𝘁 𝘁𝗼 𝗗𝗼

• Create real marketing assets (social media, campaigns, event visuals)
• Design scientific infographics that simplify complex ideas
• Work directly with marketing & technical teams (yes, your work will go live)
• Contribute to branding, campaigns, and industry events

🔥 𝗪𝗵𝗼 𝗪𝗲’𝗿𝗲 𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗙𝗼𝗿

• Final year students / fresh grads in Graphic Design, Multimedia, or related field
• Creative thinkers with a strong eye for design
• Comfortable with tools like Adobe Illustrator, Photoshop, Canva
• Curious about science, healthcare, or technology (big plus)
• Someone who wants more than just an “internship”

🌱 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗜𝗻𝘁𝗲𝗿𝗻𝘀𝗵𝗶𝗽 𝗶𝘀 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁

• Your designs will be used in real-world healthcare and genomics campaigns
• You’ll build a portfolio that actually impresses employers
• Exposure to precision medicine, biotech, and innovation
• Work in a fast-growing, ambitious team

📍 Bukit Jalil, Kuala Lumpur
📩 Send your CV & portfolio to: info@agtcgenomics.com

💬 If you’ve ever thought:
“I want my designs to do more than just look good…”

👉 Come design the future of healthcare with us.

18/04/2026

🚀 𝗦𝘁𝗮𝗿𝘁 𝗬𝗼𝘂𝗿 𝗖𝗮𝗿𝗲𝗲𝗿 𝗪𝗵𝗲𝗿𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗠𝗲𝗲𝘁𝘀 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗜𝗺𝗽𝗮𝗰𝘁
𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗶𝘀 𝗛𝗶𝗿𝗶𝗻𝗴 – 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁 (𝗙𝗿𝗲𝘀𝗵 𝗚𝗿𝗮𝗱𝘂𝗮𝘁𝗲𝘀 𝗪𝗲𝗹𝗰𝗼𝗺𝗲!)

Not all jobs are created equal.
Some are just jobs.
This one? It’s a launchpad.

At AGTC Genomics, you won’t just learn — you’ll build, engage, and shape the future of precision medicine.

💡 Imagine this:

• Working with cutting-edge genomics technologies
• Engaging directly with clinicians, scientists, and innovators
• Being part of a team that is transforming how diseases are detected, treated, and prevented

🔥 What You’ll Do

• Drive adoption of advanced genomics solutions across hospitals, labs, and research institutions
• Build real relationships with doctors, scientists, and decision-makers
• Be involved in presentations, strategy, and market expansion
• Gain exposure to oncology, liquid biopsy, pharmacogenomics, and more

🌱 Who Should Apply

• Fresh graduates (or up to 1 year experience) in Life Sciences, Biotech, Biomedical, or related fields
• Curious, driven, and not afraid to talk to people
• Want more than a routine job — you want growth, exposure, and purpose

💼 Why Join AGTC Genomics

• Work in a fast-growing precision medicine company
• Get real industry exposure early in your career
• Learn beyond textbooks — from real clinical and commercial impact
• Be part of a young, dynamic, and ambitious team

📍 Location: Bukit Jalil, Kuala Lumpur
📩 Send your CV to: info@agtcgenomics.com

💬 If you’ve ever thought:
“I want to do something meaningful with my science degree…”

This is your moment.

👉 Join us. Build the future. Not just a career.

18/04/2026

𝗣𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗼𝗲𝘀𝗻’𝘁 𝗔𝗹𝘄𝗮𝘆𝘀 𝗦𝗵𝗼𝘄 𝗦𝘆𝗺𝗽𝘁𝗼𝗺𝘀 𝗘𝗮𝗿𝗹𝘆. 𝗬𝗼𝘂𝗿 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗦𝗵𝗼𝘂𝗹𝗱.

Prostate cancer often develops silently—with many patients only diagnosed after PSA changes or symptoms appear.

By then, valuable time may already be lost.

With AGTC Genomics CancerScreenDx, our Multi-Cancer Early Detection (MCED) test enables:
✔ Early cancer signal detection from a simple blood draw
✔ Complementary insights alongside PSA testing
✔ Detection before clinical symptoms become evident
✔ Multi-cancer screening in a single test

This is not about replacing PSA.
This is about enhancing early detection with precision genomics.

🚀 Why Clinics Are Moving Beyond PSA Alone
• Identify high-risk patients earlier—even with borderline PSA
• Reduce uncertainty in routine prostate monitoring
• Strengthen your men’s health screening programs
• Offer next-generation diagnostics patients are actively seeking
• Create new high-value preventive care revenue streams

🚨 Opportunity for Clinics & Doctors

• Expand your preventive health portfolio
• Differentiate your practice with advanced genomics
• Increase patient retention with proactive screening programs
• Generate new revenue streams with high-value diagnostics

Don’t wait for late-stage cases.
Start detecting earlier. Start saving more lives.

📩 Partner with AGTC Genomics today
📍 Deploy CancerScreenDx in your clinic
🔬 Backed by advanced NGS & precision medicine expertise

18/04/2026

𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗦𝗵𝗼𝘂𝗹𝗱𝗻’𝘁 𝗦𝘁𝗮𝗿𝘁 𝗪𝗵𝗲𝗻 𝗦𝘆𝗺𝗽𝘁𝗼𝗺𝘀 𝗔𝗽𝗽𝗲𝗮𝗿

By the time a lump is felt or imaging becomes suspicious,
the window for the earliest intervention may already be narrowing.

Your clinic can move ahead of that curve.

With AGTC Genomics CancerScreenDx (MCED), you can now offer:
✔ Early cancer signal detection from a simple blood test
✔ Identify risk even before imaging findings
✔ Multi-cancer screening in one streamlined workflow
✔ A powerful complement to mammography and ultrasound

This is not replacing screening.
This is elevating your entire preventive care strategy.

🚨 Opportunity for Clinics & Doctors

• Expand your preventive health portfolio
• Differentiate your practice with advanced genomics
• Increase patient retention with proactive screening programs
• Generate new revenue streams with high-value diagnostics

Don’t wait for late-stage cases.
Start detecting earlier. Start saving more lives.

📩 Partner with AGTC Genomics today
📍 Deploy CancerScreenDx in your clinic
🔬 Backed by advanced NGS & precision medicine expertise

17/04/2026

𝗖𝗼𝗹𝗼𝗿𝗲𝗰𝘁𝗮𝗹 𝗖𝗮𝗻𝗰𝗲𝗿 𝗜𝘀 𝗣𝗿𝗲𝘃𝗲𝗻𝘁𝗮𝗯𝗹𝗲. 𝗟𝗮𝘁𝗲 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 𝗜𝘀𝗻’𝘁.

Too many colorectal cancer cases are still detected after symptoms appear—when intervention is more complex, costly, and less effective.

Your clinic can change that.

With AGTC Genomics CancerScreenDx (MCED), you can now offer:
✔ Early cancer signal detection from a simple blood test
✔ Screening before symptoms like bleeding or bowel changes occur
✔ Multi-cancer detection in one workflow—no additional burden
✔ Seamless integration into preventive health programs

This is more than screening.
This is a shift from reactive care to proactive medicine.

🚨 Opportunity for Clinics & Doctors

Expand your preventive health portfolio
Differentiate your practice with advanced genomics
Increase patient retention with proactive screening programs
Generate new revenue streams with high-value diagnostics

Don’t wait for late-stage cases.
Start detecting earlier. Start saving more lives.

📩 Partner with AGTC Genomics today
📍 Deploy CancerScreenDx in your clinic
🔬 Backed by advanced NGS & precision medicine expertise

17/04/2026

𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗼𝗲𝘀𝗻’𝘁 𝗪𝗮𝗶𝘁. 𝗪𝗵𝘆 𝗦𝗵𝗼𝘂𝗹𝗱 𝗬𝗼𝘂?

Most lung cancer cases are diagnosed too late—when treatment options are limited and outcomes are poorer.

Your patients deserve better.

With AGTC Genomics CancerScreenDx (MCED), you can now offer:
✔ Early detection from a simple blood test
✔ Cancer signal identification before symptoms
✔ Multi-cancer screening in a single workflow
✔ Actionable insights to guide next clinical steps

This is not just screening.
This is practice-changing preventive care.

🚨 Opportunity for Clinics & Doctors

Expand your preventive health portfolio
Differentiate your practice with advanced genomics
Increase patient retention with proactive screening programs
Generate new revenue streams with high-value diagnostics

Don’t wait for late-stage cases.
Start detecting earlier. Start saving more lives.

📩 Partner with AGTC Genomics today
📍 Deploy CancerScreenDx in your clinic
🔬 Backed by advanced NGS & precision medicine expertise

15/04/2026

🚀 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗛𝗲𝗮𝗹𝘁𝗵 𝗦𝘁𝗮𝗿𝘁𝘀 𝗡𝗼𝘄: 𝗥𝗲𝗱𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗶𝗻 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮

AGTC Genomics is honoured to be part of the 1st Regional Conference on Precision Health (RCPH), organized by Universiti Kebangsaan Malaysia (UKM) and UKM Medical Molecular Biology Institute (UMBI)—a timely and important platform that brings together leaders across healthcare, research, and industry to shape the future of precision medicine in our region.

This conference reflects a growing national and regional commitment to transform healthcare from reactive to predictive, preventive, and personalized. As the burden of complex diseases continues to rise, precision health is no longer optional—it is essential.

At AGTC Genomics, we remain focused on driving this transformation through:
🔬 High-quality, clinically actionable genomic solutions
🧬 Integration of advanced sequencing technologies into routine care
📊 Translating data into meaningful insights for better patient outcomes
🌏 Expanding access to precision diagnostics across Malaysia and Southeast Asia

Events like RCPH play a critical role in aligning stakeholders, accelerating innovation, and ensuring that the benefits of precision health reach more patients, faster.

Together, we move closer to a future where the right test, at the right time, at the right price becomes the standard of care.